Loading
Life sciences · Journal article
Health Science Reports · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Antimicrobial resistance (AMR) is one of the most urgent global public health threats, especially in low‐ and middle‐income countries. In 2019, bacterial AMR was estimated to have directly caused approximately 1.27 million deaths and to have been associated with 4.95 million deaths worldwide. Rapid identification of resistant infections is important, yet established diagnostics are very slow. In recent years, artificial intelligence (AI) has revolutionized microbiology and infectious disease diagnostics. This review explores the space of AI‐enabled diagnostics for AMR detection and characterization. Methods This literature review was conducted from January to September 2026 using PubMed/MEDLINE, Google Scholar, and other electronic databases with keywords including “AI,” “AMR,” “deep learning,” “genomic diagnostics,” and “point‐of‐care (POC) testing.” Following screening and full‐text assessment, 67 Peer‐reviewed articles and systematic reviews were included to support the synthesis presented in the manuscript, while non‐peer‐reviewed articles and studies lacking direct AI relevance were excluded. Titles and abstracts were screened before full‐text review. Results AI‐enhanced diagnostics were reported to shorten turnaround time for AMR detection with promising but heterogeneous predictive performance; for example, pooled estimates across antimicrobial stewardship applications indicate an area under the curve of approximately 0.72. They also support improving antimicrobial stewardship and enable early therapeutic optimization in laboratory and POC settings, enabling real‐time clinical decision‐making. Despite these achievements, evidence for direct improvements in patient outcomes and routine bedside effectiveness remains limited. Conclusion AI‐driven diagnostic tools represent a promising strategy to bridge laboratory innovation and bedside application in combating AMR. The tools have the capacity to improve patient outcomes and enhance antimicrobial stewardship as they can accurately detect resistance patterns and support real‐time clinical decisions. However, long‐term sustainability, long‐term success, and global impact can be achieved by continued validation, regulatory alignment, and equitable implementation across diverse healthcare settings.